Sep 02, 2024 15:12 JST

Source: Eisai

Eisai Announces Status Relating to Acquisition of Own Shares

Eisai Co., Ltd. announced today that it has acquired its own shares based on Article 40 of its Articles of Incorporation pursuant to the provisions of Article 459, paragraph 1 of the Companies Act. The status (progress report) of the acquisition is as described below.

1. Class of shares acquired: Ordinary shares of the Company
2. Total number of shares acquired: 1,598,800 shares
3. Aggregate amount of acquisition cost: JPY9,100,754,577
4. Acquisition period: From August 1 to August 31, 2024 (execution basis)
5. Acquisition method: Open market purchase through the Tokyo Stock Exchange based on a discretionary trading contract

For Reference

1. Resolution at a meeting of the Board of Directors held on May 15, 2024

(1) Class of shares to be acquired: Ordinary shares of the Company
(2) Total number of shares to be acquired: 6,500,000 shares (maximum)
(Ratio to total number of issued shares (excluding treasury shares): 2.3%)
(3) Total amount of acquisition cost: JPY30.0 billion (maximum)
(4) Period of acquisition: From May 16, 2024 to November 15, 2024
(5) Acquisition method: Open market purchase through the Tokyo Stock Exchange based on a discretionary trading contract

2. Accumulated number and price of own shares acquired in accordance with the above mentioned resolution at the meeting of Board of Directors (as of August 31, 2024)
(1) Total number of shares acquired: 4,037,300 shares
(2) Aggregate amount of acquisition cost: JPY24,933,137,242

Source: Eisai
Sectors: Healthcare & Pharm

Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
September 17 2025 17:20 JST
 
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
September 12 2025 12:20 JST
 
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
September 08 2025 16:49 JST
 
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
September 04 2025 09:56 JST
 
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
September 03 2025 10:32 JST
 
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
September 01 2025 12:44 JST
 
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
August 29 2025 17:17 JST
 
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)
August 25 2025 18:30 JST
 
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
August 18 2025 08:11 JST
 
Revenue of LEQEMBI(R) (Preliminary Basis)
July 31 2025 17:27 JST
 
More Press release >>

Latest Press Release


More Latest Release >>